{"id":"activated-t-lymphocytes","_chembl":{"chemblId":"CHEMBL2106049","moleculeType":"Small molecule","molecularWeight":"12.01"},"modality":"Small molecule","_dailymed":null,"mechanism":{"explanation":"The therapy involves collecting T-cells from patients or donors, activating them outside the body through various stimulation methods, and reinfusing them to mount an enhanced immune response. Activated T-cells can recognize specific antigens and mediate cytotoxic effects against diseased cells.","oneSentence":"T-lymphocytes are activated ex vivo to enhance their ability to recognize and eliminate target cells through immune-mediated mechanisms."},"_scrapedAt":"2026-03-28T05:48:53.732Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123425,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"tisagenlecleucel","brand":"Kymriah","company":"Novartis","rationale":"CAR-T cell therapy targeting CD19 for hematologic malignancies"},{"name":"axicabtagene ciloleucel","brand":"Yescarta","company":"Gilead/Kite","rationale":"CAR-T cell therapy for B-cell lymphomas"},{"name":"tumor infiltrating lymphocytes","brand":"Amtagvi","company":"Iovance","rationale":"Autologous T-cell therapy for solid tumors"}],"description":"Activated T-Lymphocytes is an investigational cell therapy developed by Banc de Sang i Teixits currently in Phase 1 clinical development. This autologous or allogeneic cellular immunotherapy involves ex vivo activation of T-cells to enhance immune response against disease targets.","indications":{"approved":[{"status":"investigational","condition":"Unknown","patientPopulation":"Unknown"}]},"trialDetails":[{"nctId":"NCT03721068","phase":"PHASE1","title":"Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-02-19","conditions":"Neuroblastoma, Osteosarcoma","enrollment":18},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT03533816","phase":"PHASE1","title":"Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2020-01-31","conditions":"Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia","enrollment":38},{"nctId":"NCT03910452","phase":"EARLY_PHASE1","title":"Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-10-28","conditions":"Chronic Granulomatous Disease","enrollment":4},{"nctId":"NCT02503423","phase":"PHASE1, PHASE2","title":"Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2015-07-14","conditions":"Solid Tumors, Lymphoma","enrollment":253},{"nctId":"NCT07101328","phase":"PHASE1","title":"A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 )","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-06","conditions":"Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse","enrollment":215},{"nctId":"NCT03827343","phase":"","title":"Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-01-23","conditions":"Macrophage Activation Syndrome, Primary Hemophagocytic Lymphohistiocytosis","enrollment":500},{"nctId":"NCT07175441","phase":"PHASE2","title":"Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Riboscience, LLC.","startDate":"2026-04","conditions":"Advanced Unresectable Hepatocellular Carcinoma","enrollment":220},{"nctId":"NCT06071624","phase":"PHASE1","title":"Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.","status":"RECRUITING","sponsor":"Huda Salman","startDate":"2024-02-21","conditions":"Chronic Myelomonocytic Leukemia","enrollment":30},{"nctId":"NCT05098132","phase":"PHASE1, PHASE2","title":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","status":"RECRUITING","sponsor":"Synthekine","startDate":"2022-01-25","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC","enrollment":364},{"nctId":"NCT07481136","phase":"PHASE1","title":"64Cu-GRIP B in Patients With Acute Myocarditis","status":"NOT_YET_RECRUITING","sponsor":"Javid Moslehi, MD","startDate":"2026-08","conditions":"Acute Myocarditis","enrollment":10},{"nctId":"NCT07477366","phase":"PHASE2","title":"Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-04","conditions":"Relapsed B-Cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT06823596","phase":"NA","title":"The T Cell Activator of Cell Killing (\"TACK\") IT ON\" STUDY","status":"RECRUITING","sponsor":"University of Toronto","startDate":"2025-01-14","conditions":"Hiv","enrollment":26},{"nctId":"NCT07475182","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study of Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers","status":"RECRUITING","sponsor":"Hainan Cancer Hospital","startDate":"2025-12-06","conditions":"Advanced Solid Cancers","enrollment":10},{"nctId":"NCT06483048","phase":"PHASE1","title":"MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-09-20","conditions":"Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma","enrollment":12},{"nctId":"NCT07137494","phase":"PHASE1","title":"A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-08-14","conditions":"Primary Central Nervous System (CNS) Lymphoma, Secondary Central Nervous System Lymphoma","enrollment":12},{"nctId":"NCT07125872","phase":"PHASE2","title":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-11-11","conditions":"Relapsed B-Cell Non Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT06946680","phase":"PHASE1","title":"IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Pediatric High-grade Glioma (HGG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-03-18","conditions":"High-grade Glioma","enrollment":18},{"nctId":"NCT07464951","phase":"PHASE1","title":"CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Stephan Grupp MD PhD","startDate":"2026-04-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":30},{"nctId":"NCT07461181","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Efficacy of CS01 in Patients With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-30","conditions":"Locally Advanced or Metastatic Solid Tumors","enrollment":10},{"nctId":"NCT07257419","phase":"PHASE1","title":"CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03-03","conditions":"Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy","enrollment":60},{"nctId":"NCT05353530","phase":"PHASE1","title":"IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2023-07-25","conditions":"Glioblastoma Multiforme, Glioblastoma","enrollment":39},{"nctId":"NCT07217301","phase":"PHASE3","title":"IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed","status":"RECRUITING","sponsor":"Fortvita Biologics (USA)Inc.","startDate":"2025-11-26","conditions":"iO Resistant sqNSCLC","enrollment":600},{"nctId":"NCT03849651","phase":"PHASE2","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-01-31","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)","enrollment":69},{"nctId":"NCT06692426","phase":"PHASE1","title":"Trial of Cell Based Therapy for DMD","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2025-03-20","conditions":"Duchenne Muscular Dystrophy","enrollment":8},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT07223541","phase":"PHASE2","title":"Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2026-01-15","conditions":"Clear Cell Renal Cell Carcinoma","enrollment":72},{"nctId":"NCT07437534","phase":"PHASE4","title":"Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Hayat Abad Medical Complex, Peshawar","startDate":"2026-03-01","conditions":"Atopic Dermatitis","enrollment":148},{"nctId":"NCT04969887","phase":"PHASE2","title":"Combination Immunotherapy in Rare Cancers Under InvesTigation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Olivia Newton-John Cancer Research Institute","startDate":"2021-08-03","conditions":"Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm","enrollment":240},{"nctId":"NCT03272334","phase":"PHASE1, PHASE2","title":"Her2-BATS and Pembrolizumab in Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Virginia","startDate":"2017-12-29","conditions":"Metastatic Breast Cancer","enrollment":22},{"nctId":"NCT05255601","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-09-13","conditions":"Lymphoma, Non-Hodgkin, Hodgkin Disease","enrollment":5},{"nctId":"NCT02744287","phase":"PHASE1","title":"Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-11-30","conditions":"Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer","enrollment":52},{"nctId":"NCT07416240","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer.","status":"RECRUITING","sponsor":"Hainan Cancer Hospital","startDate":"2026-02-18","conditions":"Advanced Pancreatic Cancer","enrollment":10},{"nctId":"NCT06191887","phase":"PHASE1","title":"B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-18","conditions":"B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":27},{"nctId":"NCT05676697","phase":"PHASE1","title":"PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy","status":"TERMINATED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-01-13","conditions":"Autoimmune Hemolytic Anemia, Failure of Two Rounds of Treatment","enrollment":4},{"nctId":"NCT04690595","phase":"PHASE1","title":"BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"PeproMene Bio, Inc.","startDate":"2021-05-18","conditions":"Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia","enrollment":24},{"nctId":"NCT04963283","phase":"PHASE2","title":"Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-06-23","conditions":"Colorectal Adenocarcinoma, Colon Cancer, Colon Adenocarcinoma","enrollment":48},{"nctId":"NCT04806347","phase":"PHASE1","title":"Alpha/Beta T-cell Depleted Blood-forming Stem Cell Transplant From Related or Unrelated Donors for Blood Diseases in Children and Young Adults","status":"NOT_YET_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-04","conditions":"Blood Disease","enrollment":12},{"nctId":"NCT07105059","phase":"PHASE1","title":"A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-08-08","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT04080804","phase":"PHASE2","title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2019-12-20","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":80},{"nctId":"NCT03965468","phase":"PHASE2","title":"Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-11-19","conditions":"Non-small Cell Lung Cancer, Stage IV, Oligometastasis","enrollment":96},{"nctId":"NCT05872854","phase":"PHASE2","title":"Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light","status":"COMPLETED","sponsor":"Ellen Kim, MD","startDate":"2023-08-21","conditions":"Cutaneous T Cell Lymphoma, Mycosis Fungoides","enrollment":10},{"nctId":"NCT07392073","phase":"","title":"Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-04","conditions":"Non-Small Cell Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma","enrollment":80},{"nctId":"NCT01625351","phase":"PHASE1","title":"A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-08-20","conditions":"Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor","enrollment":23},{"nctId":"NCT03203473","phase":"PHASE2","title":"Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Toni Choueiri, MD","startDate":"2017-10-26","conditions":"Renal Cancer","enrollment":85},{"nctId":"NCT05418972","phase":"PHASE2","title":"A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2023-08-14","conditions":"Stage II Melanoma","enrollment":20},{"nctId":"NCT07386912","phase":"","title":"Investigation of the Effects of Oxidized Antigens on the T-Cell Response and the Epigenetic Reprogramming of Neutrophils in Lung Diseases - OXIGENE -","status":"NOT_YET_RECRUITING","sponsor":"Research Center Borstel","startDate":"2026-02-01","conditions":"Asthma, COPD, Bacterial Pneumonia","enrollment":100},{"nctId":"NCT05460533","phase":"PHASE2","title":"A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-07-12","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT00709033","phase":"PHASE1","title":"T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2009-07","conditions":"Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia","enrollment":3},{"nctId":"NCT04745559","phase":"PHASE2","title":"Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-02-18","conditions":"Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL)","enrollment":26},{"nctId":"NCT03279692","phase":"PHASE2","title":"Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2017-11-07","conditions":"High Grade Meningioma","enrollment":26},{"nctId":"NCT03356470","phase":"","title":"Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-11-02","conditions":"Melanoma","enrollment":5},{"nctId":"NCT04989946","phase":"PHASE1, PHASE2","title":"Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-12-16","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT07087002","phase":"PHASE1","title":"GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-08-28","conditions":"Medulloblastoma, Central Nervous System Embryonal Tumor, Refractory Medulloblastoma","enrollment":18},{"nctId":"NCT07319676","phase":"PHASE1, PHASE2","title":"Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2026-01-31","conditions":"B-cell Lymphoma Refractory","enrollment":30},{"nctId":"NCT03829540","phase":"PHASE1","title":"CD4CAR for CD4+ Leukemia and Lymphoma","status":"RECRUITING","sponsor":"Huda Salman","startDate":"2020-07-09","conditions":"T-cell Lymphoma, T-cell Leukemia","enrollment":20},{"nctId":"NCT07189936","phase":"PHASE2","title":"Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-12-18","conditions":"Post-Acute COVID-19 Syndrome, Postural Tachycardia Syndrome (POTS), SARS CoV 2 Infection","enrollment":50},{"nctId":"NCT06197672","phase":"PHASE1","title":"Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"Huda Salman","startDate":"2024-03-19","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT03333616","phase":"PHASE2","title":"Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-12-28","conditions":"Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder","enrollment":100},{"nctId":"NCT06962631","phase":"PHASE3","title":"V-IMMUNE® for Immune Thrombocytopenia","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-07-18","conditions":"Immune Thrombocytopenia (ITP)","enrollment":31},{"nctId":"NCT06954441","phase":"PHASE3","title":"V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-08-15","conditions":"Immunodeficiencies, Primary Immunodeficiencies (PID), Agammaglobulinemia","enrollment":50},{"nctId":"NCT06731504","phase":"EARLY_PHASE1","title":"HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT","status":"RECRUITING","sponsor":"Duke University","startDate":"2025-11-12","conditions":"Hematologic Malignancy","enrollment":10},{"nctId":"NCT04530123","phase":"PHASE2","title":"Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-06-23","conditions":"Celiac Disease","enrollment":102},{"nctId":"NCT07345208","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of ID vs IM Rabies Vaccine","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-12-15","conditions":"Rabies","enrollment":90},{"nctId":"NCT05544968","phase":"PHASE1","title":"Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-03","conditions":"Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30+ Anaplastic Large Cell Lymphoma","enrollment":42},{"nctId":"NCT05400109","phase":"PHASE1","title":"Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"David Wald","startDate":"2023-04-26","conditions":"Non Hodgkin Lymphoma","enrollment":21},{"nctId":"NCT06295159","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-05-17","conditions":"Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma","enrollment":90},{"nctId":"NCT07321847","phase":"PHASE2, PHASE3","title":"Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Immunophotonics, Inc.","startDate":"2026-05","conditions":"Colorectal Cancer (CRC), Colon Cancer Liver Metastases, Rectal Cancer","enrollment":717},{"nctId":"NCT01853631","phase":"PHASE1","title":"Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2014-02","conditions":"Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia","enrollment":64},{"nctId":"NCT07266116","phase":"PHASE1, PHASE2","title":"Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients","status":"RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2025-12-26","conditions":"Systemic Light Chain Amyloidosis","enrollment":70},{"nctId":"NCT07052370","phase":"PHASE1","title":"TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-09-25","conditions":"Hematologic Malignancy","enrollment":30},{"nctId":"NCT06219616","phase":"NA","title":"Prediction of BK Virus Reactivation in Kidney Transplant Recipient","status":"COMPLETED","sponsor":"King Chulalongkorn Memorial Hospital","startDate":"2023-05-01","conditions":"Kidney Transplant Infection, BK Virus Infection, BK Virus Nephropathy","enrollment":80},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT04165941","phase":"PHASE1","title":"Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2020-02-11","conditions":"Brain Tumor Adult","enrollment":22},{"nctId":"NCT06824064","phase":"PHASE2","title":"Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer","status":"RECRUITING","sponsor":"Riboscience, LLC.","startDate":"2025-01-17","conditions":"Metastatic Colorectal Cancer, Advanced Colorectal Cancer","enrollment":150},{"nctId":"NCT04670068","phase":"PHASE1","title":"Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2021-01-27","conditions":"Epithelial Ovarian Cancer","enrollment":4},{"nctId":"NCT03388632","phase":"PHASE1","title":"Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-05","conditions":"Metastatic Solid Tumors, Treatment-Refractory Cancers","enrollment":31},{"nctId":"NCT04688658","phase":"PHASE1, PHASE2","title":"Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma","status":"TERMINATED","sponsor":"John Kirkwood","startDate":"2021-10-06","conditions":"Unresectable Melanoma","enrollment":13},{"nctId":"NCT03622788","phase":"PHASE1, PHASE2","title":"Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-08-08","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia","enrollment":16},{"nctId":"NCT04664179","phase":"PHASE1","title":"EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2022-10-31","conditions":"EBV-Related Hodgkin Lymphoma, EBV-Related Lymphoproliferative Disorder, EBV Related Non-Hodgkin's Lymphoma","enrollment":52},{"nctId":"NCT03952637","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis","status":"RECRUITING","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2019-08-19","conditions":"Lysosomal Diseases, Gangliosidosis, GM1","enrollment":54},{"nctId":"NCT07179679","phase":"PHASE1","title":"A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-12-09","conditions":"Multiple Myeloma","enrollment":42},{"nctId":"NCT05329337","phase":"NA","title":"Link Between the Peripheral Mononuclear Cells' Capacity to Induce Insulin Resistance and Hyperinsulinemia","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2022-06-27","conditions":"Insulin Resistance, Hyperinsulinism, Immune System","enrollment":30},{"nctId":"NCT02374242","phase":"PHASE2","title":"Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2014-11-04","conditions":"Melanoma, Brain Metastases","enrollment":76},{"nctId":"NCT07271121","phase":"PHASE2","title":"Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL","status":"RECRUITING","sponsor":"King Hussein Cancer Center","startDate":"2025-02-12","conditions":"Non-Hodgkin Lymphoma Refractory/ Relapsed","enrollment":26},{"nctId":"NCT03367962","phase":"PHASE1","title":"Detection of Graft Versus Host Disease With [18F]F-AraG","status":"COMPLETED","sponsor":"CellSight Technologies, Inc.","startDate":"2018-05-15","conditions":"Graft Versus Host Disease","enrollment":9},{"nctId":"NCT03696784","phase":"PHASE1","title":"Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-03-12","conditions":"Lymphoma, Lymphoma, B-Cell, Immune System Diseases","enrollment":19},{"nctId":"NCT05089370","phase":"PHASE1, PHASE2","title":"Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2022-06-20","conditions":"Malignant Melanoma","enrollment":8},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT07264075","phase":"PHASE3","title":"Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN","status":"NOT_YET_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2026-01","conditions":"Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)","enrollment":780},{"nctId":"NCT05010005","phase":"PHASE1","title":"A Study of Ruxolitinib and Duvelisib in People With Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-08-12","conditions":"T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia","enrollment":70},{"nctId":"NCT07249073","phase":"EARLY_PHASE1","title":"CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-28","conditions":"Multiple Myeloma","enrollment":9},{"nctId":"NCT03307785","phase":"PHASE1","title":"Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-10-12","conditions":"Neoplasms, Metastatic Cancer, Advanced Cancer","enrollment":60},{"nctId":"NCT07242482","phase":"","title":"Circulating Immune Markers for Prognostic Evaluation in Postoperative Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Zhao Jun","startDate":"2025-12-17","conditions":"Lung Cancer (Diagnosis), Biomarkers / Blood","enrollment":200},{"nctId":"NCT05370430","phase":"PHASE1","title":"BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL","status":"RECRUITING","sponsor":"PeproMene Bio, Inc.","startDate":"2022-06-13","conditions":"Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","enrollment":36},{"nctId":"NCT07240194","phase":"PHASE2","title":"The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09-01","conditions":"Large B-cell Lymphoma, TP53","enrollment":24},{"nctId":"NCT06455917","phase":"PHASE2","title":"TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-01-22","conditions":"Non-Small Cell Lung Cancer, Lung Cancer (NSCLC)","enrollment":30},{"nctId":"NCT04520711","phase":"PHASE1","title":"Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2022-02-08","conditions":"Malignant Epithelial Neoplasms","enrollment":24},{"nctId":"NCT03573700","phase":"PHASE1, PHASE2","title":"Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2018-07-24","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory","enrollment":24},{"nctId":"NCT01857934","phase":"PHASE2","title":"Therapy for Children With Advanced Stage Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-07-05","conditions":"Neuroblastoma","enrollment":153}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2538,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Activated T-Lymphocytes","genericName":"Activated T-Lymphocytes","companyName":"Banc de Sang i Teixits","companyId":"banc-de-sang-i-teixits","firstApprovalDate":"","aiSummary":"Activated T-Lymphocytes are a type of immune cell studied in various clinical trials for conditions such as transplant failure, metastatic cancer, and lymphoma. They are targeted by small molecule interventions, including Sym021 and Sym022, which are being investigated in clinical trials for these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}